Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.

Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J; EuroSIDA Study Group.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70. doi: 10.1097/QAI.0b013e3181e9be6b.

PMID:
20700060
2.

Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group.

Mocroft AJ, Lundgren JD, d'Armino Monforte A, Ledergerber B, Barton SE, Vella S, Katlama C, Gerstoft J, Pedersen C, Phillips AN.

Int J Epidemiol. 1997 Apr;26(2):400-7.

PMID:
9169177
3.

Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study.

Serraino D, Zucchetto A, Suligoi B, Bruzzone S, Camoni L, Boros S, De Paoli A, Dal Maso L, Franceschi S, Rezza G.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):99-105. doi: 10.1097/QAI.0b013e3181a4f663.

PMID:
19448558
4.

Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.

Reekie J, Kosa C, Engsig F, Monforte Ad, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A; EuroSIDA Study Group.

Cancer. 2010 Nov 15;116(22):5306-15. doi: 10.1002/cncr.25311.

5.

The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.

d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M; Antiretroviral Therapy Cohort Collaboration.

Arch Intern Med. 2005 Feb 28;165(4):416-23. Erratum in: Arch Intern Med. 2005 May 23;165(10):1200.

PMID:
15738371
6.

Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?

Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration).

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):158-65.

PMID:
11588510
7.

Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial Group.

Pueyo S, Salmi LR, Chêne G, Leport C, Morlat P, Dequae L, Grégoire V, Hafner R, Vildé JL, Luft BJ, Aubertin J, Salamon R.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):459-64.

PMID:
9170421
8.

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.

Am J Epidemiol. 2002 Apr 15;155(8):760-70.

PMID:
11943695
9.

Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.

Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Muñoz A.

Am J Epidemiol. 2003 Oct 1;158(7):687-94.

PMID:
14507605
10.

[EuroSIDA Study: downward trend of AIDS cases and AIDS mortality].

Blasko M.

Dtsch Med Wochenschr. 2003 Sep 5;128(36):1814. German. No abstract available.

PMID:
14518432
11.

Mortality and progression to AIDS after starting highly active antiretroviral therapy.

van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F; ATHENA Cohort Study Group.

AIDS. 2003 Oct 17;17(15):2227-36.

PMID:
14523280
12.

[Decline in AIDS and death rates in the EuroSIDA study. An observational study].

Kirk O, Mocroft A, Lundgren JD; EuroSIDA-studiet.

Ugeskr Laeger. 2004 Jun 21;166(26-31):2572-6. Danish. No abstract available.

PMID:
15285167
13.

Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.

Mocroft A, Sabin CA, Youle M, Madge S, Tyrer M, Devereux H, Deayton J, Dykhoff A, Lipman MC, Phillips AN, Johnson MA.

J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):401-7.

PMID:
10458621
14.

The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.

Mocroft A, Youle M, Phillips AN, Halai R, Easterbrook P, Johnson MA, Gazzard B.

Arch Intern Med. 1998 Mar 9;158(5):491-7.

PMID:
9508227
15.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR 3rd; Pediatric AIDS Clincial Trials Group Protocol 219C Team.

Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87.

PMID:
16894075
16.
17.
18.

The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS.

Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S.

Am J Epidemiol. 2007 May 15;165(10):1143-53. Epub 2007 Mar 6.

PMID:
17344204
19.

Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy.

Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ; National HIV Surveillance Committee.

AIDS. 2003 Jul 4;17(10):1539-45.

PMID:
12824792
20.

Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.

Cain LE, Cole SR, Chmiel JS, Margolick JB, Rinaldo CR Jr, Detels R.

Am J Epidemiol. 2006 Feb 15;163(4):310-5. Epub 2005 Dec 21.

PMID:
16371516

Supplemental Content

Support Center